Table 1

Baseline characteristics

CharacteristicsPlacebo group
(n = 91)Otelixizumab group
(n = 181)
Age, years25.3 ± 7.224.8 ± 6.6
Sex, n (%)
 Female31 (34.1)64 (35.4)
 Male60 (65.9)117 (64.6)
Ethnicity, n (%)
 Hispanic/Latin American3 (3.3)8 (4.4)
 Non-Hispanic/Latin American88 (96.7)173 (95.6)
Race, n (%)
 American Indian or Alaska Native0 (0)1 (0.6)
 Asian2 (2.2)1 (0.6)
 African American2 (2.2)6 (3.3)
 Multiracial2 (2.2)4 (2.2)
 Caucasian85 (93.4)169 (93.4)
BMI, kg/m223.6 ± 3.023.6 ± 3.3
Weight, kg72.2 ± 12.271.9 ± 14.6
HbA1c
 %7.26 ± 1.557.25 ± 1.29
 mmol/mol56 ± 16.956 ± 14.1
Time-normalized stimulated C-peptide AUC, (nmol/L × min)/min*0.70 ± 0.360.75 ± 0.42
Maximum stimulated C-peptide, nmol/L*1.00 ± 0.511.03 ± 0.55
  • Data are the mean ± SD, unless otherwise specified.

  • *Placebo n = 90; otelixizumab n = 179.